Metastatic signet-ring cell cancer of the bladder responding to chemotherapy with capecitabine: case report and review of literature

Authors

  • Jorg Michels Medical Oncologist, Vancouver Island Centre, British Columbia Cancer Agency, Victoria, BC
  • Sean Barbour Internal Medicine resident, UBC Division of Nephrology, Vancouver, BC
  • Douglas Cavers Pathologist (retired), Department of Laboratory Medicine and Pathology, Vancouver Island Health Authority, Victoria, BC
  • Kim N. Chi Medical Oncologist, Vancouver Centre, British Columbia Cancer Agency, Vancouver, BC

DOI:

https://doi.org/10.5489/cuaj.831

Abstract

Signet-ring cell cancers deriving from the bladder are rare entities and usually present with advanced incurable disease and associated poor outlook. No standard effective chemotherapeutic option has been described largely due to the rarity of this malignancy. We report a case of a patient with metastatic bladder cancer, signet-ring cell variant. The patient progressed rapidly on standard first-line bladder cancer chemotherapy with gemcitabine and carboplatin. He responded well to second-line capecitabine with a clinically meaningful progression-free survival.

Downloads

Download data is not yet available.

Author Biographies

Jorg Michels, Medical Oncologist, Vancouver Island Centre, British Columbia Cancer Agency, Victoria, BC

Sean Barbour, Internal Medicine resident, UBC Division of Nephrology, Vancouver, BC

Douglas Cavers, Pathologist (retired), Department of Laboratory Medicine and Pathology, Vancouver Island Health Authority, Victoria, BC

Kim N. Chi, Medical Oncologist, Vancouver Centre, British Columbia Cancer Agency, Vancouver, BC

Downloads

How to Cite

Michels, J., Barbour, S., Cavers, D., & Chi, K. N. (2013). Metastatic signet-ring cell cancer of the bladder responding to chemotherapy with capecitabine: case report and review of literature. Canadian Urological Association Journal, 4(2), E55-E57. https://doi.org/10.5489/cuaj.831

Issue

Vol. 4 No. 2 (2010): CUAJ April

Section

Case Report

License

You, the Author(s), assign your copyright in and to the Article to the Canadian Urological Association. This means that you may not, without the prior written permission of the CUA:

  • Post the Article on any Web site
  • Translate or authorize a translation of the Article
  • Copy or otherwise reproduce the Article, in any format, beyond what is permitted under Canadian copyright law, or authorize others to do so
  • Copy or otherwise reproduce portions of the Article, including tables and figures, beyond what is permitted under Canadian copyright law, or authorize others to do so.

The CUA encourages use for non-commercial educational purposes and will not unreasonably deny any such permission request.

You retain your moral rights in and to the Article. This means that the CUA may not assert its copyright in such a way that would negatively reflect on your reputation or your right to be associated with the Article.

The CUA also requires you to warrant the following:

  • That you are the Author(s) and sole owner(s), that the Article is original and unpublished and that you have not previously assigned copyright or granted a licence to any other third party;
  • That all individuals who have made a substantive contribution to the article are acknowledged;
  • That the Article does not infringe any proprietary right of any third party and that you have received the permissions necessary to include the work of others in the Article; and
  • That the Article does not libel or violate the privacy rights of any third party.